Clinical Trials Browser

Has results × Prostatic Neoplasms × pembrolizumab × Clear all

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Phase 2 Active not recruiting

58 enrolled 13 charts

Prostatic Neoplasms

NCT03007732 2025-12-05

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2 Completed

23 enrolled 14 charts

Prostatic Neoplasms

NCT04090528 2025-12-05

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Phase 2 Active not recruiting

60 enrolled 10 charts

Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03582475 2025-11-12

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Phase 1 Active not recruiting

15 enrolled 17 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Prostatic Neoplasms, Urethral Neoplasms

NCT03834493 2025-07-18

KEYNOTE-641

Phase 3 Active not recruiting

1,244 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834506 2025-07-18

KEYNOTE-921

Phase 3 Completed

1,030 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT03093428 2025-03-28

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

Phase 2 Completed

45 enrolled 12 charts

Prostatic Neoplasms

NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2 Terminated

205 enrolled 54 charts

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT03805594 2025-02-25

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

43 enrolled 20 charts

Prostatic Neoplasms

NCT03248570 2024-11-20

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Phase 2 Completed

26 enrolled 18 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04907227 2024-07-12

KEYNOTE-921

Phase 3 Terminated

81 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02325557 2024-04-02

ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1/2 Completed

50 enrolled 14 charts

Neoplasms, Prostatic Neoplasms

NCT02499835 2023-08-01

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Phase 1/2 Completed

66 enrolled 18 charts

Prostatic Neoplasms

NCT02489357 2021-11-12

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

Phase NA Completed

12 enrolled 5 charts

Prostatic Neoplasms